Asthma, rhinitis, other respiratory diseases Wine-induced asthma: A placebocontrolled

Size: px
Start display at page:

Download "Asthma, rhinitis, other respiratory diseases Wine-induced asthma: A placebocontrolled"

Transcription

1 Asthma, rhinitis, other respiratory diseases Wine-induced asthma: A placebocontrolled assessment of its pathogenesis Hassan Vally, BSc (Hons), Amanda Carr, BAppSc, Jacque El-Saleh, RN, and Philip Thompson, FRACP Perth, Australia Background: The sulfite family of food additives has been implicated in the pathogenesis of wine-induced asthma. However, the evidence supporting this is weak, and because wines have many hundreds of components, nonsulfite-associated mechanisms may also play a role. Objectives: The aim of the study was to assess the potential sensitivity of persons with asthma to nonsulfite components in wine by using low-sulfite wine challenges. Methods: Sixteen adults with a strong history of wine-induced asthma were challenged with both low-sulfite red and white wines and wine-placebo drinks. Challenges were performed double blind, using a Latin square design, with lung function being assessed before the challenge and at 5, 10, 15, 30, and 60 minutes after the challenge. Subsequently, single-blind challenges with high-sulfite white wine were also completed in 10 individuals whose lack of reactivity to low-sulfite white wine suggested possible reactivity to sulfite additives. Results: The mean FEV 1 ; forced expiratory flow, mid-expiratory phase; and peak expiratory flow of subjects to low-sulfite red and white wines and red and white placebo wines were not significantly different. Furthermore, with a predetermined criterion of a fall in FEV 1 of more than 15% representing a positive challenge, only one individual exhibited a positive reaction in the presence of a negative response to placebo. Only 2 of the 10 test individuals who were challenged with a high-sulfite wine demonstrated a marked and rapid fall in FEV 1. Reactivity to low-sulfite wines appears to occur only in a small number of individuals who report sensitivity to wines, suggesting that the sulfite additives may be the major cause of wine-induced asthmatic reactions. However, direct challenge with high-sulfite wine revealed only 2 clear reactions in this asthma cohort. Conclusion: Wine-induced asthma appears to be a complex phenomenon and may involve several mechanisms that are codependent. (J Allergy Clin Immunol 1999;103:41-6.) Key words: Asthma, sulfite, wine From the Asthma and Allergy Research Unit, Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Perth. Received for publication June 4, 1998; revised Aug 3, 1998; accepted for publication Aug 3, Reprint requests: Philip J. Thompson, FRACP, Asthma and Allergy Research Unit, University Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands WA 6009, Australia. Copyright 1999 by Mosby, Inc /99 $ /1/93730 Abbreviations used FEF : Forced expiratory flow, mid-expiratory phase PEF: Peak expiratory flow VAS: Visual analogue scale Although many persons with asthma report wine as a trigger for worsening asthma symptoms, 1 little is known about the pathogenesis of these reactions. Some individuals report reactions to red wines only, others to white wines only; some individuals report reactions to both red and white wines, and certain individuals report reactions only to specific types or brands of wine. The understanding of the mechanisms of these reactions is further complicated by the fact that these drinks consist of many hundreds of components derived from the grapevine, yeast, and bacteria and from chemicals added during the processing steps. 2 Despite these confounding factors, the sulfites have been singled out as playing the major role in wine-induced asthmatic reactions. 3 Sulfites are produced by yeast during fermentation but are also added exogenously during manufacture because they have many roles, including the prevention of microbial spoilage and oxidation of these drinks. 4 Limited studies directly investigating the role of sulfites in wine-induced asthma have yielded equivocal results. 5,6 Furthermore, because sulfites may be associated with the triggering of asthmatic reactions in up to 10% of individuals with asthma 7,8 and because the prevalence of wine-induced asthma may be as high as 30%, 1 nonsulfite components of wine may be playing a major role in these reactions. The aim of this study was to assess whether nonsulfite components of wine may be triggering asthmatic reactions. Consequently, 16 subjects with a clear history of wine-induced asthma were challenged in a double-blind fashion with both placebo and low-sulfite red and white wines. Additional single-blind challenges were also conducted with high-sulfite wines and with specific problem wines to further delineate the pathophysiologic features of these reactions. METHODS Study design Sixteen individuals with stable asthma (13 women and 3 men; mean age, 33.2 ± 9.6 years; range, 23 to 53 years) were recruited into a double-blind, Latin-square designed, placebo-controlled study to assess the effect of wine consumption on airway narrowing. All subjects reported a history of repeated episodes of worsening 41

2 42 Vally et al J ALLERGY CLIN IMMUNOL JANUARY 1999 TABLE I. Patient details and history History of History of sulfite- Baseline Baseline Age Skin prick response Asthma wine food FEV 1 FEV 1 Patient Sex (y) Positive Brewer s yeast medications sensitivity sensitivity (L) (% predicted) 1 F 29 Y Y ba C,W Y M 27 Y Y ba R N F 30 Y Y ba R,W,C Y M 42 Y N ba,sm,bc R N F 26 Y Y ba,bc R N F 51 Y Y ba R,W,C,Ch Y F 27 Y Y ba,bu R,W,C N M 29 Y Y ba W,C N F 23 Y N ba,bc R,C N F 30 Y N ba W,C,Ch N F 25 Y N ba,bc R,W,Ch Y F 39 N N ba,th W,Ch N F 28 Y N ba R,W,C N F 28 Y N ba,bc R,W,C,Ch N F 53 N N ba,bc R,W N F 45 Y Y bc,ip,cr W,C,Ch N % predicted, Percentage of predicted value; ba, β 2 -adrenoceptor agonists; C, champagne; W, white wine; R, red wine; sm, salmeterol; bc, beclomethasone; Ch, cheap wine; bu, budesonide; th, theophylline; ip, ipratropium bromide; cr, cromoglycate. asthma symptoms within 1 hour of wine consumption, but no history of reacting to spirit-based drinks. Subjects who had liver disease or serious medical conditions, who were taking medications known to interact with alcohol, or who were pregnant were excluded from the study. Patients whose adverse reactions to wine had previously resulted in hospitalization and those who had an obvious impairment in alcohol metabolism were also excluded from the study. Clinical details of asthma were recorded for all patients, and allergen skin tests were performed with a range of common allergens. All individuals entering the study had baseline spirometry assessed (Vitalograph Ltd, Buckingham, UK) and were required to have an FEV 1 greater than 70% of predicted value or an FEV 1 greater than 1.5 L. In addition, a questionnaire was completed at entry to the study to assess the patient s sensitivity to alcoholic beverages and sulfite-containing foods. Challenge drink preparation Low-sulfite wine. Commercially available low-sulfite red and white wines (BRL Hardy Wine Co., Reynella, South Australia) were used in this study. The sulfite levels of these wines were determined by the alkimetric aspiration technique, 9 with the total sulfite concentration being measured both in our laboratory and confirmed by an independent wine analysis laboratory. The total sulfite content of the low-sulfite red wine was 3.7 ± 0.9 ppm (1.9 ppm free, 1.9 ppm bound); the total sulfite level of the low-sulfite white wine was 18.9 ± 0.9 ppm (2.1 ppm free, 16.8 ppm bound). The ph of the lowsulfite wines used in this study were consistently found to be between 3.5 and 3.7. Placebo wine. Placebo red and white wine drinks were used in this study. These drinks were an enhancement of the model wine solution used by Halpern et al 5 in their challenge studies and consisted of a wine-like base containing g/l tartaric acid, g/l sugar, and 0.06 mmol/l NaOH in sterile pure water. The red wine placebo was colored by the addition of 1 g of red Anthocyanin dye per 500 ml of this base; the white wine placebo was colored by the addition of 2 to 3 drops of a stock solution of Curcumin dye (made by the dissolution of 0.2 g of Curcumin yellow to 1 ml of water). The final placebo challenge drinks were then prepared by the addition of ml of this wine-like base to 63.5 ml of vodka (37.2% alcohol/volume). Both the alcohol content (13.5% vol/vol) and final ph of these placebo drinks (ph 3.5) were matched to that of the wines used in this study. High-sulfite wine. High-sulfite wine was created by spiking lowsulfite white wine with sodium metabisulfite (Na 2 S 2 O 5 ) to increase the sulfite concentration to 300 ppm. The addition of sulfite was facilitated through the agency of a sulfite stock solution. Confirmation of sulfite level of the high-sulfite wine was completed with the alkimetric aspiration sulfite assay and was found to be ± 12.4 ppm (238.9 ppm free, 51.7 ppm bound). Freshly made high-sulfite wine was used for each study day. A preliminary study confirmed that there was no loss of sulfite and no appreciable change in the proportion of free to bound sulfite over the period of each study day. Challenge procedure Double-blind low-sulfite wine challenge. Subjects were instructed to eat a light meal 2 hours before each challenge and to abstain from all alcoholic beverages for at least 48 hours. The use of medications was also restricted before each challenge day; short-acting β 2 -agonists were restricted for 8 hours; cromolyn/nedocromil, inhaled steroids, and anticholinergics were restricted for 12 hours; long-acting β 2 -agonists and short-acting antihistamines were restricted for 24 hours; and theophylline was restricted for 3 days before the challenge. Challenges were conducted at least 48 hours but less then 8 days apart and at the same time of day (±1 hour). The challenge on each occasion involved the steady ingestion of 175 ml of the alcoholic drink over a period of 3 minutes. All of the challenge drinks were consumed at room temperature. Baseline FEV 1 was assessed at the beginning of each study day and was required to be within 10% of the baseline FEV 1 at entry into the study. Lung function measurements were then taken at 5, 10, 15, 30, and 60 minutes after wine challenge. The best of 3 measurements was recorded for each time point. A fall in FEV 1 more than 15% from prechallenge values was predetermined as a positive response to challenge in the individual; a fall in FEV 1 of more than 25% resulted in the mandatory withdrawal of the subject from the study day and the administration of appropriate bronchodilatory therapy.

3 J ALLERGY CLIN IMMUNOL VOLUME 103, NUMBER 1, PART 1 Vally et al 43 Single-blind high-sulfite wine challenge. After excluding patients who reacted to placebo wine challenges, 10 of the remaining 14 patients undertook a high-sulfite wine challenge. Singleblind high-sulfite wine challenges were conducted in a similar fashion to the double-blind wine challenges described earlier, but with the following modifications. After equilibration for 5 minutes at room temperature, 150 ml of cooled white wine (4 o C) was consumed over a period of 5 minutes. Lung function measurements began immediately after the completion of the wine drink (5 minutes), with additional measurements at 15, 30, and 60 minutes after challenge. A fall in FEV 1 of more than 15% (from prechallenge values) was considered representative of a positive response to challenge; lung function measurements were halted if this was observed. Single-blind challenge with specific problem wines. Three subjects who had no reaction to low-sulfite wine challenges or to highsulfite wine challenges were subsequently challenged in singleblind fashion with specific wines to which they had reported reactions in the previous 12 months. Challenges were performed in a similar fashion to that described for the single-blind high-sulfite wine challenges. However, to closely mimic exposures to wines as they occur in social settings, red wines were consumed at room temperature, and white wines were consumed after being chilled to 4 C. The appropriate low-sulfite wine to which the subject had previously demonstrated nonreactivity was used as the placebo in these studies; the order of these challenges was randomized. Subjective measurement of patient responses to wine challenge After the double-blind placebo-controlled challenges to low-sulfite wines, subjects were asked to mark on a visual analogue scale (VAS) the degree to which they felt they had reacted. The VAS was anchored at the left with no (reaction) at all and at the right with much worse (reaction) than usual. All responses were recorded as a score from 1 to 100, based on the distance in millimeters from the left. Individuals were also required to assess the degree to which specific asthma symptoms were experienced, both before and after the challenge with a VAS for each of the following 4 parameters: cough, chest tightness, shortness of breath, and wheeze. Statistics The InStat statistics program (Graphpad Software, San Diego, Calif) was used to generate mean (SEM) values, and the differences between means were assessed for statistical significance with the Student t test. Correlations were determined with Spearman s rank correlation. Ethics The study was reviewed and approved by the Committee for Human Rights of the University of Western Australia. The protocol was explained, and informed consent was obtained from all subjects taking part in this study. RESULTS Subjects Twenty-two self-reporting wine-sensitive individuals with asthma were screened; of these, 16 completed the study. Of those not completing the study, 2 subjects did not meet wine-sensitivity history requirements on interview, 3 subjects were withdrawn because of unstable asthma, and 1 subject was withdrawn because of an adverse event unrelated to the study protocol. Subject details and histories of the 16 recruited subjects are summarized in Table I. Fourteen subjects were atopic as demonstrated by FIG 1. Change in FEV 1 in response to red wine (filled boxes) and red wine placebo (open boxes) in subject 3. Baseline FEV 1 is represented by the horizontal dashed line. skin prick tests, with 8 subjects reacting to brewer s yeast. The subjects histories of wine reactivity were disparate; 7 individuals indicated a history of asthmatic reactions to both red and white wines, 5 to white wines only, and 4 to red wines only. In addition, 9 individuals specifically identified cheaper brands of wine as worsening their asthma symptoms to a greater degree than more expensive wines. With the criteria of consistent asthmatic reactions to at least 2 different sulfite-containing foods, 4 subjects in this study were classified as sulfite sensitive. Double-blind low-sulfite wine challenge Lung function measurements. No significant difference was observed in the maximum fall in FEV 1, forced expiratory flow, mid-expiratory phase (FEF ), or peak expiratory flow (PEF) after challenge with each of the low-sulfite wines and respective placebo wines (Table II). However, with the predetermined criterion of a fall in FEV 1 of more than 15% as representing a positive response, 3 subjects reacted to one or more of the challenges. Subject 3 exhibited a positive reaction to the lowsulfite red wine challenge, with the FEV 1 falling 24.2% from baseline within 5 minutes (Fig 1). The other 2 positive reactors exhibited reactions to wine challenges and to one of the placebo challenges. Subject 5 exhibited a positive response to the red wine challenge, the placebo red wine challenge, and the white wine challenge, with maximum falls in FEV 1 of 29.1%, 19.0%, and 17.4%, respectively; subject 14 exhibited a positive response to the red wine challenge and the placebo white wine challenge, with maximum falls in FEV 1 of 19.4% and 18.7% for each of these challenges, respectively. Perception of reactions. The VAS responses correlated significantly with the measured maximal fall in FEV 1 (r s, 0.54; P <.0001; Fig 2). All subjects experiencing a fall in FEV 1 in response to the wine challenge indicated a significant alteration in their asthma symptoms on the VAS. In subject 3, who recorded a clear reaction to lowsulfite red wine, there was an equal increase in intensity (by 25 mm) for all 4 of the assessed asthma parameters.

4 44 Vally et al J ALLERGY CLIN IMMUNOL JANUARY 1999 FIG 2. Scattergram shows the VAS scores recorded by subjects with asthma in response to wine challenges (n = 16). Bars indicate mean values. Subjects 4, 6, 13, and 16 perceived a significant reaction to one or more of the challenges (VAS scores, 46 to 90 mm) that was not accompanied by a decline in spirometric measurements. Single-blind high-sulfite wine challenge Ten individuals who took part in the first part of this study received an additional high-sulfite white wine challenge (placebo controlled). Subjects 3 and 11 responded to the high-sulfite wine challenge and also provided a history strongly suggestive of a sensitivity to sulfite additives in foods. Both of these positive responses to highsulfite wine challenges were marked, with FEV 1 falling by more than 40% (from baseline) within 5 minutes (Fig 3). Interestingly, subject 3 reacted to the low-sulfite red wine challenge and to the high-sulfite white wine challenge but not to the placebo wines, suggesting that 2 separate pathways may underlie the sensitivity to wines in this one individual. It is also interesting to note that subjects 1 and 6, who provided a history strongly suggestive of sulfite sensitivity, did not demonstrate a significant decline in FEV 1 after the high-sulfite wine challenge (Fig 3). The lung function in subject 1 remained steady after the wine challenge; in subject 6, the FEV 1 fell rapidly by 11.2% within 5 minutes before recovering to baseline levels by 15 minutes. In subject 15, a positive reaction to the high-sulfite wine challenge was observed; however, lung function measurements (FEV 1 < 90% of baseline) and a clinical interview indicated the individual s asthma had changed considerably between this challenge and the previous low-sulfite wine challenge. Consequently, a low-sulfite wine challenge was repeated, and significantly this individual exhibited reactivity to this second challenge (Fig 4). FIG 3. Change in FEV 1 in response to high-sulfite wine challenge in subjects who provided a food history suggestive of a sensitivity to sulfites: subject 1 (open circles), subject 3 (filled boxes),subject 6 (filled circles), subject 11 (open boxes), and the average change in FEV 1 in response to low-sulfite challenge in these subjects, n = 4 (*). Baseline FEV 1 represented by the horizontal dashed line. Single-blind challenge with specific problem wines A further single-blind challenge was completed with specific brands of wine to which individuals had reported reactions in the previous 12 months. Unfortunately, many subjects found it difficult to identify the specific wine triggering their asthmatic reactions, and only 3 (of a possible 8) individuals were able to participate. Two of the 3 individuals (subjects 1 and 8) identified specific white wine triggers and did not respond to challenge; subject 15, who identified a specific red wine trigger, exhibited a reaction that was not significant (Fig 5). DISCUSSION We investigated the role of the nonsulfite components of wine in wine-induced asthmatic reactions by challenging individuals in a double-blind fashion with both red and white low-sulfite wines and wine placebo drinks. Using 3 measures of airway narrowing (FEV 1, PEF, and FEF ), we were unable to demonstrate a significant decline in the mean lung function parameters of this study group in response to a challenge with low-sulfite wines compared with placebo wines. However, defining a positive response as a fall in FEV 1 of more than 15%, we observed a reaction to low-sulfite red wine in one subject. This response was rapid in onset, with FEV 1 declining by 24.2% in 5 minutes, and suggested that this individual may be sensitive to a component present in low-sulfite red wine. One such component is histamine, which is present in red wines to a much higher degree than in white wine, and is a potent mediator of allergic responses. 10 Although ingested histamine has been shown to play a role in intolerance and asthmatic reactions to wines in susceptible individuals, 10,11 the extent of this is not clear. Whether histamine played a role in this specific patient is not known; however, the kinetics of this reaction suggests otherwise. Plasma levels of histamine in intolerant individuals have been found to peak between 20 minutes and 30 minutes after a challenge and therefore symptoms initiated by this mediator would be expected to follow a similar time course. 11 Studies of

5 J ALLERGY CLIN IMMUNOL VOLUME 103, NUMBER 1, PART 1 Vally et al 45 FIG 4. Response of subject 15 to high-sulfite wine challenge (filled boxes) and to repeat low-sulfite wine challenges, challenge 1 (open boxes) and challenge 2 (open triangles). FIG 5. Responsiveness of 3 subjects to specific problem wines: subject 1 (filled triangles), subject 8 (open boxes), subject 15 (filled boxes), and the average change in FEV 1 in response to control challenges, n = 3 (*). Baseline FEV 1 represented by horizontal dashed line. TABLE II. Mean maximal fall in FEV 1, FEF 25-75, and PEF in response to wine challenge Red wine (%) Red placebo (%) White wine (%) White placebo (%) FEV (± 2.4) 3.82 (± 1.5) 2.96 (± 1.6) 3.00 (± 1.5) FEF (± 5.1) (± 3.3) 9.66 (± 4.8) 7.78 (± 3.9) PEF 8.12 (± 2.2) 5.12 (± 1.9) 3.31 (± 2.1) 3.78 (± 1.7) Means are expressed as a percentage of baseline values (± SEM). other components in wines capable of inducing asthmatic reactions must be pursued. 3 The overall lack of reactivity to low-sulfite wine challenges suggested that the sulfites might be playing a major role in the asthmatic responses to wines reported by subjects in this study. However, we were unable to demonstrate this, because only 2 individuals exhibited asthmatic reactions to high-sulfite wine challenge. In contrast, Dahl et al 6 suggested sulfites were playing a role in the reactions of 9 of 18 red wine sensitive subjects with asthma who were challenged. This finding is surprising because white wines usually have much higher sulfite concentrations than red wines and therefore suggests other components in red wines may have been potentiating the responses to the sulfites in these individuals. In the study by Dahl et al, 6 no difference was seen in the responsiveness of individuals to low-sulfite red wines (total sulfur dioxide concentration, 50 to 55 ppm) with differing amine levels. However, the only high-sulfite wine challenge to be undertaken (total sulfur dioxide concentration, 265 to 275 ppm) was also extremely high in amine content (8.5 to 9.5 mg/l). Therefore the possible role of biogenic amines in potentiating high-sulfite red wine responses is not clear. Significantly, we challenged subjects with white wines, which differ chemically from red wines and generally have a much lower amine concentration, 10 which may explain the smaller number of sulfite reactors found in our study. However, whether other agents are capable of potentiating responses to the sulfites in wines, 12 or alternatively, whether other factors influence individual s reactivity to the sulfites in wines 13 is not clear. Importantly, the 2 positive responses to high-sulfite wines in this study were marked and rapid, indicating an exquisite sensitivity in some individuals to the sulfites present in wines. The most intriguing aspect of the present study was the number of individuals who, despite clear histories of wine sensitivity, remained unresponsive to a challenge. Of the 10 individuals challenged with placebo, low-sulfite wines, and high-sulfite wines, 7 individuals remained unresponsive. A similar result was obtained by Dahl et al 6 with 9 of 18 subjects not responding to a challenge with a series of modified red wines despite a clear clinical history. The reasons for the lack of reactivity to formal challenge in both our study and that of Dahl et al 6 suggest that other factors may be playing an important role in these reactions. Some individuals may react to wines only when their asthma is unstable. Dahl et al 6 described pollen-sensitive asthmatics who only reacted to red wines in the pollen season, when presumably their asthma was less stable. In this study, one subject exhibited a positive response to the high-sulfite wine challenge at a time when both clinical interview and baseline lung function measurements indicated that there had been a change in asthma severity. A low-sulfite wine challenge at this stage was also positive, despite a previous low-sulfite challenge being negative. Therefore baseline asthma severity seems to have influenced the reactivity of this individual to low-sulfite white wine. Anecdotally, many

6 46 Vally et al J ALLERGY CLIN IMMUNOL JANUARY 1999 subjects described more noticeable reactions to wine when their asthma symptoms were less stable, and conversely, being able to tolerate wines on occasions when their asthma was well controlled. Because strict criteria regarding asthma severity and stability were required to enter this study, it is possible this may have contributed to the overall paucity of positive responses to challenge. Importantly, baseline asthma severity did not seem to influence reactivity to the sulfites, which was supported by the 2 sulfite responders exhibiting a baseline FEV 1 greater than 100% of predicted value. 14,15 Environmental cofactors may also play a role in asthmatic reactions to wines. That is, drinking wine may potentiate asthmatic responses to cigarette smoke or other irritants or vice versa. Blinded challenges in 3 of our subjects with specific wines to which they had previously reacted to failed to precipitate a significant fall in lung function when challenged with these same wines in a clinical setting (Fig 5). In subjects 1 and 8, specific white wine triggers failed to stimulate a change in lung function or in subjective measures of worsening asthma. In subject 15, the challenge with a specific red wine trigger caused a nonsignificant fall in the FEV 1 ( 13.5%), and difficulty in breathing was observed, but this was not to the same degree as had previously been experienced with this particular wine. Increases in bronchial hyper-reactivity after exposure to food or food chemicals have been reported by various investigators However, whether wine exposure results in increased bronchial reactivity is unknown. In trying to explain the number of nonreactors, it is important to note that a number of individuals reported changes in their asthma symptoms in response to a challenge that were not reflected in lung function measurements. This may indicate that spirometric measurement alone may not be sensitive enough to pick up reactions to wines in all individuals. 19 Only 2 individuals responded to placebo wine in this study, suggesting that a psychologic or nonspecific mechanism of reactivity is unlikely to explain the large number of patients who report sensitivity to wines. The results of this study highlight the complex nature of wine-induced asthma. We were able to demonstrate reactivity in 2 individuals to the sulfites in white wine, with one of these individuals also reacting to a specific component present only in the low-sulfite red wine. Two individuals exhibited reactions to placebo wine challenges, suggesting either a nonspecific or psychologic component to their reactions. One individual exhibited an inconsistent response to low-sulfite white wine, which seemed related to asthma severity at the time of challenge. Most intriguing, however, was that, from a cohort of selfreported wine-sensitive individuals with asthma, 7 of 10 subjects who were challenged with both low- and highsulfite wines did not demonstrate a reaction to any of the challenges delivered. Whether this lack of reactivity to a formal challenge is indicative of cofactors that play an important role in these reactions (eg, unstable asthma or environmental triggers, such as cigarette smoke or other allergens) or whether patient histories are unreliable is unclear at this stage and requires further investigation. The authors thank BRL Hardy Wine Co. for the donation of the preservative-free wines used in this study, and Christian Hansen Pty. Ltd. for supplying the food coloring used in the making of placebo wines. REFERENCES 1. Ayres J, Clarke TJH. Alcoholic drinks and asthma: a survey. Br J Dis Chest 1983;77: Zuskin E, Mustajbegovic J, Schachter E, Kern J, Pavicic D. Respiratory function in vineyard workers. Am J Ind Med 1997;31: Gershwin M, Ough C, Bock A, Fletcher MP, Nagy SM, Tuft DS. Grand rounds: adverse reactions to wine. J Allergy Clin Immunol 1985;75: Romano P, Suzzi G. Sulfur dioxide and wine microorganisms. In: Fleet GH, editor. Wine microbiology and biotechnology. Chur: Harwood Academic Publishers; p Halpern G, Gershwin E, Ough C, Fletcher MP, Nagy SM. The effect of white wine upon pulmonary function of asthmatic subjects. Ann Allergy 1985;55: Dahl R, Henriksen JM, Harving H. Red wine asthma: a controlled challenge study. J Allergy Clin Immunol 1986;78: Stevenson D, Simon RA. Sulfites and asthma. J Allergy Clin Immunol 1984;74: Bush RK, Taylor SL, Holden K, Nordlee JA, Busse WW. Prevalence of sensitivity to sulfiting agents in asthmatic patients. Am J Med 1986;81: Rankine B. New method for determining sulfur dioxide in wine. Aust Wine Brew & Spirit Rev 1962;80: Wantke F, Hemmer W, Haglmuller T, Gotz M, Jarisch R. The red wine provocation test: intolerance to histamine as a model for food intolerance. Allergy Proc 1994;15: Wantke F, Hemmer W, Haglmuller T, Gotz M, Jarisch R. Histamine in wine. Int Arch Allergy Immunol 1996;110: Evans DJ, Coulby LJ, O Connor BJ. Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulfite in mild asthma. Thorax 1996;51: Delohery J, Simmul R, Castle WD, Allen D. The relationship of inhaled sulfur dioxide reactivity to ingested metabisulfite sensitivity in patients with asthma. Am Rev Respir Dis 1984;130: Wright W, Zhang YG, Salome CM, Woolcock AJ. Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite. Am Rev Respir Dis 1990;141: Field P, McClean M, Simmul R, Berend N. Comparison of sulfur dioxide and metabisulfite airway reactivity in subjects with asthma. Thorax 1994;49: Wilson N, Vickers H, Taylor G, Silverman M. Objective test for food sensitivity in asthmatic children: increased bronchial reactivity after cola drinks. Br Med J 1982;284: Hariparsad D, Wilson N, Dixon C, Silverman M. Oral tartrazine challenge in childhood asthma: effect on bronchial reactivity. Clin Allergy 1984;14: Wilson NM, Dixon C, Silverman M. Increased bronchial responsiveness caused by ingestion of ice. Eur J Respir Dis 1985;66: Corder EH, Buckley CE. Aspirin, salicylate, sulfite and tartrazine induced bronchoconstriction: safe doses and case definition in epidemiological studies. J Clin Epidemiol 1995;48:

Asthma Management for the Athlete

Asthma Management for the Athlete Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric

More information

Food related asthma: a difference between two ethnic groups

Food related asthma: a difference between two ethnic groups Archives of Disease in Childhood, 1985, 60, 861-865 Food related asthma: a difference between two ethnic groups N M WILSON Department of Paediatrics and Neonatal Medicine, Royal Postgraduate Medical School,

More information

Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid

Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid 12 Paediatrics and Child Health, Dunedin School of Medicine, PO Box 913, University of Otago Medical School, Dunedin, New Zealand J Garrett Preventive and Social Medicine, Dunedin School of Medicine S

More information

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to

More information

Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical

More information

Get Healthy Stay Healthy

Get Healthy Stay Healthy Asthma Management WHAT IS ASTHMA? Asthma causes swelling and inflammation in the breathing passages that lead to your lungs. When asthma flares up, the airways tighten and become narrower. This keeps the

More information

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D. Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL Bronchial asthma MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL DEFINITION ASTHMA BRONCHIALE = Asthma is a chronic inflammatory disorder of the airways in which

More information

Some Facts About Asthma

Some Facts About Asthma Some Facts About Asthma Contents What is asthma? Diagnosing asthma Asthma symptoms Asthma triggers Thanks What is asthma?? Asthma is a chronic lung-disease that inflames and narrows the airways (tubes

More information

Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm

Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm

More information

Significance. Asthma Definition. Focus on Asthma

Significance. Asthma Definition. Focus on Asthma Focus on Asthma (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Asthma Definition Chronic inflammatory disorder of airways Causes airway hyperresponsiveness

More information

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,

More information

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review

More information

Lecture Notes. Chapter 3: Asthma

Lecture Notes. Chapter 3: Asthma Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.

SUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE. i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment

More information

Budesonide treatment of moderate and severe asthma in children: A doseresponse

Budesonide treatment of moderate and severe asthma in children: A doseresponse Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate

More information

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS. DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms

More information

Meenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar

Meenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1267 ISSN 1175 8716 Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand Catherina L Chang, Manisha Cooray, Graham Mills,

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

Characterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma

Characterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma Thorax 1989;44:19-114 Characterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma G M NICHOL, A NIX, K F CHUNG, P J BARNES From the Department

More information

ASTHMA IN THE PEDIATRIC POPULATION

ASTHMA IN THE PEDIATRIC POPULATION ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

G. Boyd on behalf of a UK Study group

G. Boyd on behalf of a UK Study group Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in

More information

CHRONIC COUGH AS THE PRESENTING MANIFESTATION OF BRONCHIAL ASTHMA

CHRONIC COUGH AS THE PRESENTING MANIFESTATION OF BRONCHIAL ASTHMA CHRONIC COUGH AS THE PRESENTING MANIFESTATION OF BRONCHIAL ASTHMA T C Goh Dept of Medicine Toa Payoh Hospital Singapore 1129 T C Goh, MBBS, MRCP (UK), AM Registrar SYNOPSIS Bronchial asthma may present

More information

ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides

ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper

More information

Tips on managing asthma in children

Tips on managing asthma in children Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma

More information

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which

More information

Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases

Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases OBSTRUCTIVE THE IRAQI POSTGRADUATE AIRWAY MEDICAL DISEASES JOURNAL Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases Muhammed.W.AL.Obaidy *, Kassim Mhamed Sultan*,Basil Fawzi

More information

Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study

Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study European Review for Medical and Pharmacological Sciences 2005; 9: 125-131 Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study R. CARBONE, F. LUPPI *, A. MONSELISE **, G. BOTTINO

More information

LONGITUDINAL STUDY OF LUNG FUNCTION DEVELOPMENT IN A COHORT OF INDIAN MEDICAL STUDENTS: INTERACTION OF RESPIRATORY ALLERGY AND SMOKING

LONGITUDINAL STUDY OF LUNG FUNCTION DEVELOPMENT IN A COHORT OF INDIAN MEDICAL STUDENTS: INTERACTION OF RESPIRATORY ALLERGY AND SMOKING Indian J Physiol Pharmacol 1991; 35(1): 44-48 LONTUDINAL STUDY OF LUNG FUNCTION DEVELOPMENT IN A COHORT OF INDIAN MEDICAL STUDENTS: INTERACTION OF RESPIRATORY ALLERGY AND SMOKING S. WALTER* AND J. RICHARD**

More information

Respiratory Health L O O K, F E E L A N D L I V E B E T T E R

Respiratory Health L O O K, F E E L A N D L I V E B E T T E R LOOK, FEEL AND LIVE BET TER Respiratory health: hay-fever and asthma Airway obstruction and symptoms in asthma and hay-fever alike are the result of inappropriate responses of the body s immune system

More information

Busselton is a coastal city in southwestern Western

Busselton is a coastal city in southwestern Western Obstructive airway disease in 46e65-year-old people in Busselton, Western Australia, 1966e2015 Arthur (Bill) Musk 1, Michael Hunter 2,3, Jennie Hui 2,4, Matthew W Knuiman 2, Mark Divitini 2, John P Beilby

More information

A preliminary assessment of nurses asthma education needs and the effect of a training. programme in an urban tertiary healthcare facility.

A preliminary assessment of nurses asthma education needs and the effect of a training. programme in an urban tertiary healthcare facility. A preliminary assessment of nurses asthma education needs and the effect of a training programme in an urban tertiary healthcare facility O O Adeyeye, Y A Kuyinu, R T Bamisile, and C I Oghama Abstract

More information

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma. ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Asthma By Mayo Clinic staff

Asthma By Mayo Clinic staff MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

Asthma in the Athlete

Asthma in the Athlete Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with

More information

Sensitivity to Sorghum Vulgare (Jowar) Pollens in Allergic Bronchial Asthma and Effect of Allergen Specific Immunotherapy

Sensitivity to Sorghum Vulgare (Jowar) Pollens in Allergic Bronchial Asthma and Effect of Allergen Specific Immunotherapy Indian J Allergy Asthma Immunol 2002; 16(1) : 41-45 Sensitivity to Sorghum Vulgare (Jowar) Pollens in Allergic Bronchial Asthma and Effect of Allergen Specific Immunotherapy Sanjay S. Pawar Shriratna Intensive

More information

Respiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing)

Respiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing) Respiratory Subcommittee of PTAC meeting held 5 February 2010 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Outcome, classification and management of wheezing in preschool children Paul L.P. Brand

Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,

More information

Respiratory Health. Asthma and COPD

Respiratory Health. Asthma and COPD Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory

More information

Bronchial Provocation Results: What Does It Mean?

Bronchial Provocation Results: What Does It Mean? Bronchial Provocation Results: What Does It Mean? Greg King 1 Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards 2065 2 Woolcock Institute of Medical Research and Sydney Medical

More information

B.A. Wilson*, O. Bar-Or**, P.M. O'Byrne +

B.A. Wilson*, O. Bar-Or**, P.M. O'Byrne + Eur Respir J, 1994, 7, 2174 2178 DOI: 10.1183/09031936.94.07122174 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 0903-1936 The effects of indomethacin

More information

Diagnosis, Treatment and Management of Asthma

Diagnosis, Treatment and Management of Asthma Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.

More information

Abstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory

Abstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories

More information

Bronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013

Bronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013 Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years

More information

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is

More information

The effect of insecticide aerosols on lung function, airway responsiveness and symptoms in asthmatic subjects

The effect of insecticide aerosols on lung function, airway responsiveness and symptoms in asthmatic subjects Eur Respir J 2; 16: 38±43 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 The effect of insecticide aerosols on lung function, airway responsiveness

More information

Practical Approach to Managing Paediatric Asthma

Practical Approach to Managing Paediatric Asthma Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis

More information

Evolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT

Evolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado

More information

Allwin Mercer Dr Andrew Zurek

Allwin Mercer Dr Andrew Zurek Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack

More information

), the dose of histamine required to provoke a fall in FEV 1. of more than 20% (PD 20

), the dose of histamine required to provoke a fall in FEV 1. of more than 20% (PD 20 Thorax 1999;54:103 107 103 Pulmonology, Isala Clinics/Weezenlanden Hospital, 00 GM Zwolle, The P L P Brand Pulmonology, Juliana The Hague, The E J Duiverman Pulmonology, Beatrix Groningen, The H J Waalkens

More information

Joint Session ACOFP and AOASM: Exercise Induced Asthma. Bruce Dubin, DO, JD, FCLM, FACOI

Joint Session ACOFP and AOASM: Exercise Induced Asthma. Bruce Dubin, DO, JD, FCLM, FACOI Joint Session ACOFP and AOASM: Exercise Induced Asthma Bruce Dubin, DO, JD, FCLM, FACOI ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please check where applicable and sign below. Provide additional pages as

More information

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,

More information

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma

More information

Prevalence of bronchial hyperresponsiveness and

Prevalence of bronchial hyperresponsiveness and Thorax 1987;42:361-368 Prevalence of bronchial hyperresponsiveness and asthma in a rural adult population A J WOOLCOCK, J K PEAT, C M SALOME, K YAN, S D ANDERSON, R E SCHOEFFEL, G McCOWAGE, T KILLALEA

More information

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent

More information

Asthma. Guide to Good Health. Healthy Living Guide

Asthma. Guide to Good Health. Healthy Living Guide Asthma Guide to Good Health Healthy Living Guide Asthma Chronic Fatigue Syndrome (CFS) Chronic Obstructive Pulmonary Disease (COPD) Coronary Artery Disease (CAD) Depression Hyperlipidemia Hypertension

More information

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test? Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard

More information

(Asthma) Diagnosis, monitoring and chronic asthma management

(Asthma) Diagnosis, monitoring and chronic asthma management Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic

More information

LOOK, FEEL AND LIVE BETTER. Respiratory Health

LOOK, FEEL AND LIVE BETTER. Respiratory Health LOOK, FEEL AND LIVE BETTER Respiratory Health Respiratory health: hay fever and asthma Airway obstruction and symptoms in asthma and hay fever alike are the result of inappropriate responses of the body

More information

In 2002, it was reported that 72 of 1000

In 2002, it was reported that 72 of 1000 REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and

More information

Exercise-Induced Bronchoconstriction EIB

Exercise-Induced Bronchoconstriction EIB Exercise-Induced Bronchoconstriction EIB Case 1 14 yo boy, freshman in high school Complains of shortness of breath 2 minutes into a mile-run in his first gym class Same complains in his 2 nd gym class

More information

Airway calibre as a confounder in interpreting

Airway calibre as a confounder in interpreting 702 Medical Department TTA 7511, State University Hospital, Copenhagen, Denmark A Dirksen F Madsen T Engel L Frolund J H Heing H Mosbech Reprint requests to: Dr A Dirksen, Department of Pulmonary Medicine

More information

Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma

Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.

More information

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR) Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of

More information

Respiratory Pharmacology

Respiratory Pharmacology Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early

More information

International Journal of Medical Science and Education pissn eissn

International Journal of Medical Science and Education pissn eissn COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,

More information

Meeting the Challenges of Asthma

Meeting the Challenges of Asthma Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial

More information

C.S. Ulrik *, V. Backer **

C.S. Ulrik *, V. Backer ** Eur Respir J, 1996, 9, 1696 1700 DOI: 10.1183/09031936.96.09081696 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Increased bronchial responsiveness

More information

Pathology of Asthma Epidemiology

Pathology of Asthma Epidemiology Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology

More information

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium Standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate (Grazax ) No. (367/07) ALK-Abellό Ltd 6 April 2007 The Scottish

More information

Bronchial Provocation Testing Using Mannitol

Bronchial Provocation Testing Using Mannitol Patient Information Leaflet Bronchial Provocation Testing Using Mannitol Information for patients, relatives and carers For more information, please contact: Cardio-Respiratory Department The York Hospital,

More information

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80) Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE

More information

ALLERGIC RHINITIS AND ASTHMA :

ALLERGIC RHINITIS AND ASTHMA : ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs

More information

Does ketotifen have a steroid-sparing effect in childhood asthma?

Does ketotifen have a steroid-sparing effect in childhood asthma? Eur Respir J, 1997; 1: 65 7 DOI: 1.1183/931936.97.1165 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 93-1936 Does ketotifen have a steroid-sparing

More information

Screening for acetaldehyde dehydrogenase 2 genotype in alcoholinduced asthma by using the ethanol patch test

Screening for acetaldehyde dehydrogenase 2 genotype in alcoholinduced asthma by using the ethanol patch test Screening for acetaldehyde dehydrogenase 2 genotype in alcoholinduced asthma by using the ethanol patch test Hiroto Matsuse, MD, a Terufumi Shimoda, MD, a Chizu Fukushima, MD, a Kazuko Mitsuta, MD, a Tetsuya

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of

More information

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?

Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen

More information

COPD and environmental risk factors other than smoking. 14. Summary

COPD and environmental risk factors other than smoking. 14. Summary COPD and environmental risk factors other than smoking 14. Summary Author : P N Lee Date : 7 th March 2008 1. Objectives and general approach The objective was to obtain a good insight from the available

More information

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES: TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY

More information

Asthma Assessment & Review

Asthma Assessment & Review ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:

More information

Asthma: diagnosis and monitoring

Asthma: diagnosis and monitoring Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly

More information

Skin prick testing: Guidelines for GPs

Skin prick testing: Guidelines for GPs INDEX Summary Offered testing but where Allergens precautions are taken Skin prick testing Other concerns Caution Skin testing is not useful in these following conditions When skin testing is uninterpretable

More information

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype

More information

COPD and Asthma: Similarities and differences Prof. Peter Barnes

COPD and Asthma: Similarities and differences Prof. Peter Barnes and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton

More information

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy

More information

Sergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy.

Sergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy. Assessment of EIA in the community and in athletes: the role of standardized questionnaires Sergio Bonini Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy se.bonini@gmail.com

More information